Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV

J Antimicrob Chemother. 2023 Mar 2;78(3):853-854. doi: 10.1093/jac/dkad009.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • HIV Infections* / drug therapy
  • Healthy Volunteers
  • Humans
  • Rilpivirine / therapeutic use

Substances

  • Rilpivirine
  • Anti-HIV Agents